10-K: Vaxcyte Advances VAX-31 to Phase 3, Secures $632.5M Funding

Vaxcyte initiated multiple Phase 3 trials for its 31-valent pneumococcal vaccine candidate, VAX-31, following positive Phase 1/2 results and expanded Breakthrough Therapy Designation, while also raising $632.5 million in a public offering.

Summary

• Vaxcyte is a clinical-stage vaccine innovation company focused on engineering high-fidelity vaccines using its XpressCF cell-free protein synthesis platform.
• The company's pipeline includes broad-spectrum pneumococcal conjugate vaccine (PCV) candidates VAX-31, VAX-24, and VAX-XL, targeting the approximately $8 billion global pneumococcal vaccine market.
• VAX-31, a 31-valent PCV, is designed to cover approximately 95% of Invasive Pneumococcal Disease (IPD) and 88% of pneumococcal pneumonia in U.S. adults aged 50 and older, and 92% of IPD in U.S. children under five.
• Positive topline results from a Phase 1/2 study of VAX-31 in adults were announced in September 2024, showing it was well-tolerated and demonstrated robust OPA immune responses for all 31 serotypes.
• The FDA granted Breakthrough Therapy Designation (BTD) for VAX-31 for the prevention of IPD in adults in November 2024, and expanded it to include the prevention of pneumonia caused by Streptococcus pneumoniae in August 2025.
• Vaxcyte initiated a Phase 3 pivotal trial (OPUS-1) for VAX-31 in adults in December 2025, with topline data expected in Q4 2026.
• Additional Phase 3 trials for VAX-31 in adults (OPUS-2 and OPUS-3) were initiated in January and February 2026, respectively, with data expected in H1 2027.
• For the pediatric indication, VAX-24's infant Phase 2 study showed robust, dose-dependent immune responses, with final data announced in November 2025.
• The VAX-31 infant Phase 2 study completed enrollment in January 2026, with topline data expected by the end of H1 2027.
• The company plans to initiate a Phase 1 adult study for VAX-A1, a novel Group A Streptococcus vaccine candidate, in 2026.
• Advancement of VAX-GI, a preclinical vaccine candidate for dysentery and shigellosis, has been paused beyond preclinical development to prioritize the PCV franchise.
• Vaxcyte completed an underwritten public offering in February 2026, generating gross proceeds of $632.5 million.
• Net losses were $766.6 million for the year ended December 31, 2025, compared to $463.9 million in 2024, with an accumulated deficit of $2.2 billion as of December 31, 2025.
• Cash, cash equivalents, and investments totaled $2.44 billion as of December 31, 2025, which is believed to fund operating plans for at least 12 months from the filing date.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive report, driven by strong clinical data for VAX-31 leading to multiple Phase 3 initiations and expanded Breakthrough Therapy Designation, coupled with a substantial capital raise that significantly strengthens the company's financial runway for continued development and commercialization efforts.

Positives

• VAX-31 received Breakthrough Therapy Designation (BTD) from the FDA for the prevention of Invasive Pneumococcal Disease (IPD) in adults in November 2024.
• The FDA expanded VAX-31's BTD to include the prevention of pneumonia caused by Streptococcus pneumoniae in adults in August 2025.
• VAX-31's Phase 1/2 adult study showed positive topline results in September 2024, demonstrating a safety profile similar to PCV20 and robust OPA immune responses for all 31 serotypes.
• At the VAX-31 High Dose, average OPA immune responses were greater for 18 of 20 serotypes compared to PCV20, with seven achieving statistically higher responses.
• All 11 incremental serotypes unique to VAX-31 met superiority criteria in the Phase 1/2 adult study.
• Initiation of three Phase 3 pivotal trials (OPUS-1, OPUS-2, OPUS-3) for VAX-31 in adults in December 2025, January 2026, and February 2026, respectively, indicates rapid advancement towards potential licensure.
• The VAX-24 infant Phase 2 study reported positive interim data in March 2025 and final positive safety, tolerability, and immunogenicity results in November 2025, showing robust immune responses and little to no carrier suppression.
• Vaxcyte secured significant manufacturing resources through new agreements, including a commercial manufacturing agreement with Lonza (October 2023) and a custom commercial fill-finish capacity agreement with Thermo Fisher Scientific (September 2025) for its PCV candidates.
• The company obtained exclusive rights to independently develop and manufacture cell-free extract, a key component, through a manufacturing rights agreement with Sutro Biopharma in November 2023.
• A public offering in February 2026 generated approximately $600.2 million in net proceeds, significantly bolstering the company's financial position.
• The company plans to initiate a Phase 1 adult study for VAX-A1, a novel Group A Strep vaccine candidate, in 2026, demonstrating pipeline expansion.

Negatives

• Vaxcyte has incurred significant net losses since inception, with a net loss of $766.6 million in 2025 and an accumulated deficit of $2.2 billion.
• The company currently has no source of product revenue and anticipates continued substantial net losses for the foreseeable future.
• Vaxcyte will require substantial additional funding to finance operations, and there is no assurance that it will be available on acceptable terms or at all.
• The company's approach to vaccine development is based on novel technologies that are unproven, exposing it to unforeseen risks, process modifications, and unpredictable development costs and timelines.
• Vaxcyte is highly dependent on the success of its PCV candidates, and failure in development or significant delays would materially harm the business.
• The company relies heavily on third-party manufacturing and supply partners, creating risks of supply limitations, interruptions, quality issues, and compliance failures.
• The advancement of VAX-GI beyond preclinical development has been paused to prioritize resources towards the PCV franchise, potentially delaying a promising candidate.
• The vaccine market is intensely competitive, dominated by large multinational pharmaceutical companies with significantly greater resources and experience.
• VAX-24 previously experienced manufacturing delays in 2020 due to process-related matters, scheduling conflicts, and capacity constraints at Lonza.
• The company has no marketing and sales organization and no experience in marketing products, requiring significant investment or reliance on third parties for commercialization.

Risks

• Limited operating history and no products approved for commercial sale make it difficult to evaluate business success and future viability.
• Significant net losses since inception and anticipated substantial net losses for the foreseeable future, with no current source of product revenue.
• Requirement for substantial additional funding, which may not be available on acceptable terms, potentially forcing delays or termination of development programs.
• Novel technologies are unproven, exposing the company to unforeseen risks, process modifications, and difficulty predicting development time and cost.
• Vaccine candidates are in clinical or preclinical stages and may fail in development or suffer delays, materially affecting commercial viability.
• The FDA may disagree with the regulatory plan, potentially leading to failure in obtaining regulatory approval.
• High dependence on the success of PCV candidates; inability to successfully develop, obtain approval for, and commercialize them would significantly harm the business.
• Primary competitors have significantly greater resources and experience, making it difficult to successfully develop and commercialize vaccine candidates.
• Potential failure to successfully use the cell-free protein synthesis platform to expand the pipeline of vaccine candidates.
• Reliance on third-party manufacturing and supply partners for raw materials and vaccine candidates, with risks of inability to procure, insufficient quantities, delays, or non-compliance.
• The FDA regulatory approval process is lengthy and time-consuming, with potential for significant delays.
• Development, review, and approval of product candidates are subject to fluctuating operational capacity, processes, and resource levels of regulatory authorities.
• Inability to obtain and maintain broad patent protection for technology and products, or claims of infringement from third parties.
• Vaccine candidates may cause undesirable side effects or have other properties, including interactions with existing vaccine regimens, that could halt clinical development or limit commercial potential.
• Negative developments and public opinion of vaccines or new technologies may damage public perception or affect regulatory approvals.
• Difficulty enrolling subjects in clinical trials could delay or adversely affect clinical development activities.
• Interim topline and preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification.
• Failure to gain market acceptance among regulators, advisory boards, physicians, patients, and third-party payors, even if products are approved.
• Risks associated with current and potential international operations and collaborations, including differing regulatory requirements, trade policies, and currency fluctuations.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Employees, principal investigators, consultants, and commercial partners may engage in misconduct or improper activities, leading to regulatory sanctions or reputational harm.
• Changes in tax laws or tax rulings could affect the financial position.
• Ability to utilize net operating loss (NOL) carryforwards and certain other tax attributes may be limited due to ownership changes.
• Inadequate insurance policies could expose the company to unrecoverable risks.
• Compromised information technology systems or those of third parties could lead to adverse consequences, including fines, regulatory investigations, and disruptions.
• Use of artificial intelligence in operations could result in reputational or competitive harm and legal or regulatory liability.
• Natural or man-made disasters or business disruptions could seriously harm future revenue and financial condition.
• Fluctuations in financial condition and results of operations from quarter to quarter and year to year, making them difficult to predict.
• Failure to maintain proper and effective internal control over financial reporting could impair the ability to produce accurate and timely financial statements.
• Reported financial results may be adversely affected by changes in accounting principles.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research, stock price and trading volume could decline.
• Provisions in corporate charter documents and Delaware law could make an acquisition more difficult and prevent attempts by stockholders to replace management.
• Claims for indemnification by directors and officers may reduce available funds.

Future Outlook

Vaxcyte expects to announce topline safety, tolerability, and immunogenicity data from the VAX-31 adult OPUS-1 Phase 3 study in the fourth quarter of 2026. Data from the OPUS-2 and OPUS-3 studies are anticipated in the first half of 2027. Topline safety, tolerability, and immunogenicity data from the VAX-31 infant Phase 2 study are expected by the end of the first half of 2027. Subject to positive Phase 3 results, the company plans to submit a Biologics License Application (BLA) shortly after the completion of the last Phase 3 study. A Phase 3 program in infants with an Optimized Dose formulation of VAX-24 or VAX-31 is planned pending the VAX-31 infant study readout. Vaxcyte also plans to initiate a Phase 1 adult study for VAX-A1 in 2026. The company will continue to require additional capital to develop and commercialize its vaccine candidates and fund operations for the foreseeable future.

Management Comments

• We are re-engineering the way highly complex vaccines are made through the XpressCF cell-free protein synthesis platform to develop and deliver high-fidelity vaccines with enhanced immunological benefits.
• We believe VAX-31 is the broadest-spectrum PCV in the clinic, with the potential to provide protection against both currently circulating and historically prevalent serotypes.
• The final positive data from the VAX-24 infant Phase 2 dose-finding study further validated our rationale for exploring higher doses in the ongoing VAX-31 infant Phase 2 study.
• We believe high-quality and scalable manufacturing is critical to our long-term success, and our proprietary, scalable, and portable manufacturing process can scale to supply initial volumes of VAX-31 needed to support commercial launch.
• We believe we are well-positioned to obtain ACIP recommendations and potentially replace the current standard-of-care for pneumococcal disease prevention in both adult and pediatric populations, thereby creating a long-lasting PCV franchise.
• We are confident in VAX-GI's potential and are preserving the option to advance the program in the future, despite pausing its advancement beyond preclinical development to prioritize the PCV franchise.

Industry Context

StockSavvy.ai notes that the global vaccine market is large and growing, projected to reach $115.77 billion by 2033 from $72.75 billion in 2025, driven by both pediatric and rapidly expanding adult vaccination. The pneumococcal vaccine market alone generated over $1.5 billion in U.S. adult sales in 2025. Vaxcyte is positioning its VAX-31 and VAX-24 candidates to address the significant unmet medical need for broader-spectrum PCVs due to serotype replacement, a phenomenon where strains not covered by existing vaccines increase in prevalence. Competitors like Pfizer, Merck, and GSK are also developing higher-valent PCVs, indicating intense competition in this space. The Group A Strep vaccine market, targeted by VAX-A1, is estimated at $3-4 billion globally, with limited candidates in clinical development, suggesting a significant opportunity for a novel vaccine.

Comparison to Industry Standards

• VAX-31 is a 31-valent PCV, designed to provide broader coverage than current standard-of-care adult PCVs like Prevnar 20 (PCV20) and Capvaxive (PCV21), with potential incremental coverage of 14-34% for IPD and 19-31% for pneumococcal pneumonia in adults aged 50 and older.
• In its Phase 1/2 adult study, VAX-31 High Dose showed average OPA immune responses greater than PCV20 for 18 of 20 common serotypes, with seven achieving statistically higher immune responses (GMR > 1.0).
• For the 11 incremental serotypes unique to VAX-31 (not in PCV20), all three doses met superiority criteria, indicating a broader protective profile.
• VAX-24, a 24-valent PCV, covers more serotypes than any pneumococcal infant vaccine currently on the market, aiming to improve upon PCV20 and PCV15.
• The VAX-24 infant Phase 2 study demonstrated robust IgG and OPA immunogenicity responses across all doses, meeting target precedent Phase 2 non-inferiority criteria for most serotypes compared to PCV20, with little to no evidence of carrier suppression.
• Vaxcyte's cell-free protein synthesis platform and site-specific conjugation are designed to overcome limitations of conventional conjugation chemistry and carrier suppression observed in existing PCVs, which can lead to diminished immune responses with higher valency.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not presently a party to any legal proceedings that, if determined unfavorably, would have a material adverse effect on its business, financial condition, operating results, or cash flows.

Related Party Transactions

• Vaxcyte is party to an amended and restated license agreement with Sutro Biopharma, Inc. (Sutro Biopharma), dated October 12, 2015, as amended, for an exclusive, worldwide, royalty-bearing license under Sutro Biopharma's patents and know-how relating to cell-free expression of proteins for vaccine compositions. Vaxcyte is obligated to pay Sutro Biopharma a 4% royalty on worldwide aggregate annual net sales of human health vaccine products and a 2% royalty on animal health products, subject to reductions.
• Vaxcyte entered into a supply agreement with Sutro Biopharma in May 2018, as amended, to purchase extract and custom reagents for manufacturing non-clinical and certain clinical supply of vaccine compositions.
• In December 2022, Vaxcyte entered into an option grant agreement with Sutro Biopharma, paying $22.5 million upfront ($10.0 million cash, $7.5 million common stock, $5.0 million in October 2023) to obtain authorization for an independent alternate CMO for cell-free extract and an option for exclusive rights to internally manufacture/source extract.
• Vaxcyte exercised this option in November 2023, entering into a manufacturing rights agreement with Sutro Biopharma, paying $50.0 million in cash (first installment) and a final $25.0 million in May 2024. This agreement grants Vaxcyte exclusive, perpetual, royalty-free rights to manufacture or have manufactured cell-free extract for its vaccine candidates. Additional milestone payments up to $60.0 million are contingent on regulatory milestones.

Stakeholder Impact

• Shareholders: Potential for significant returns if vaccine candidates are successfully developed and commercialized, but also face substantial risks due to the speculative nature of clinical-stage biotechnology, ongoing net losses, and potential for dilution from future capital raises. Stock price volatility is a known risk.
• Employees: Opportunities for growth and career advancement within a rapidly expanding organization, supported by competitive compensation, benefits, and equity incentives. However, intense competition for skilled personnel and the at-will employment nature pose retention challenges.
• Customers (future): Access to potentially superior, broader-spectrum vaccines for pneumococcal disease and novel vaccines for diseases like Group A Strep, offering enhanced protection and addressing unmet medical needs.
• Suppliers and Contract Manufacturing Organizations (CMOs): Continued reliance on key partners like Lonza and Thermo Fisher Scientific for manufacturing and supply, providing them with significant contractual commitments and revenue streams. However, Vaxcyte's dependence on single-source suppliers creates risks for its supply chain.
• Creditors: The company's strong cash, cash equivalents, and investments position ($2.44 billion) provides a solid financial buffer, but ongoing net losses and future funding requirements indicate continued reliance on equity or debt financing.

Next Steps

• Announce topline safety, tolerability, and immunogenicity data from the VAX-31 adult OPUS-1 Phase 3 study in the fourth quarter of 2026.
• Report safety, tolerability, and immunogenicity data from the VAX-31 adult OPUS-2 and OPUS-3 studies in the first half of 2027.
• Announce topline safety, tolerability, and immunogenicity data from the VAX-31 infant Phase 2 dose-finding study by the end of the first half of 2027.
• Submit a Biologics License Application (BLA) shortly following the completion of the last VAX-31 Phase 3 study, subject to positive results.
• Initiate a Phase 3 program in infants with an Optimized Dose formulation of VAX-24 or VAX-31, pending the VAX-31 infant study readout.
• Initiate a Phase 1 adult study for VAX-A1 in 2026, with the primary objective of assessing safety and tolerability.
• Conduct a manufacturing consistency study (e.g., a lot-to-lot study) for VAX-31.
• Continue scale-up activities for VAX-31 to support potential regulatory approval and commercial launch in the adult population.
• Lonza to construct and build out a dedicated suite in Visp, Switzerland, for manufacturing key components of the PCV franchise, with commercial operations expected to commence in the future.
• Thermo Fisher Scientific to provide custom commercial fill-finish capacity for broad-spectrum PCVs at its Greenville, North Carolina facility.

Key Dates

Recommendation

Vaxcyte demonstrates strong progress with its lead PCV candidate, VAX-31, evidenced by positive Phase 1/2 adult data, expanded Breakthrough Therapy Designation, and the initiation of multiple Phase 3 trials. The company's innovative cell-free protein synthesis platform offers a differentiated approach to vaccine development, potentially yielding superior products. A substantial recent capital raise significantly strengthens its financial position, providing a runway for continued clinical development and commercialization preparations. While the company is still pre-revenue and faces inherent risks of clinical development and market competition, the positive clinical milestones and robust funding warrant a 'buy' recommendation for investors with a long-term horizon and tolerance for biotechnology sector volatility.

Keywords

Vaccine Development, Pneumococcal Conjugate Vaccine, PCV, VAX-31, VAX-24, Cell-Free Protein Synthesis, XpressCF Platform, Clinical Trials, Phase 3, Breakthrough Therapy Designation, FDA Approval, Biologics License Application, Invasive Pneumococcal Disease, Pneumonia, Group A Streptococcus, VAX-A1, Biotechnology, Pharmaceutical, Drug Manufacturing, Immunogenicity, Carrier-Sparing, Site-Specific Conjugation, Public Offering, Capital Raise